Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Carsten

Vascular Surgery Greenville, SC Medical Doctor

NPI 1275586471 CMS profile 193549

200 Patewood Dr, Suite C300, Greenville, SC 29615

Open in the dashboard

General payments

$8,492

234 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$28,718 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Christopher Carsten of Greenville, SC is reported in the CMS Open Payments database as having received $8,492 across 234 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $28,718 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 64th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,938 64
2024 General $2,395 89
2023 General $1,502 37
2022 General $817 13
2021 General $402 7
2020 General $498 8
2019 General $940 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Carsten
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Christopher Carsten were reported at $1,938. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Christopher Carsten Vascular Surgery median Middle half National median
2019 $940 $796 $226–$2,363 $163
2020 $498 $348 $118–$1,110 $114
2021 $402 $471 $158–$1,421 $132
2022 $817 $725 $222–$2,183 $149
2023 $1,502 $836 $257–$2,440 $160
2024 $2,395 $909 $252–$2,619 $164
2025 $1,938 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,224 42 payments
  2. Cook Medical LLC $1,671 48 payments
  3. Inari Medical, Inc. $1,595 71 payments
  4. Penumbra, Inc. $493 7 payments
  5. Shockwave Medical, Inc $427 6 payments
  6. Medtronic, Inc. $350 9 payments
  7. Stryker Corporation $234 10 payments
  8. Silk Road Medical, Inc. $222 1 payment
  9. Bard Peripheral Vascular, Inc. $154 4 payments
  10. RedDress USA, Inc. $144 1 payment
  11. Other $977 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,438 233 payments
  2. Travel and Lodging $54 1 payment
Products named General payments · program years 2019–2025
  1. CT THROMBECTOMY SYSTEM KIT $1,437 79 payments
  2. FLOWTRIEVER CATHETER, S $1,437 79 payments
  3. Zilver PTX $768 11 payments
  4. Conformable TAG Thoracic Endoprosthesis $409 8 payments
  5. ClotTriever $392 2 payments
  6. FlowTriever $392 2 payments
  7. GORE VIABAHN VBX Balloon Expandable Endo $323 12 payments
  8. Penumbra System $300 2 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $289 4 payments
  10. ENDURANT IIS $284 2 payments
  11. Other $4,623 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

87

Median for Vascular Surgery: 122

Drug cost

$31,538

Median for Vascular Surgery: $14,135

Branded share of claims

47.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 19 $15,744
Fondaparinux Sodium Generic 11 $15,333
Clopidogrel Clopidogrel Bisulfate Brand 22 $264
Cilostazol Generic 12 $134
Pravastatin Sodium Generic 11 $62
Atorvastatin Calcium Generic 12 $2

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 103 billing codes

Paid by Medicare

$60,432

Medicare's payments for the services billed

Medicare patients

401

Average age 73

Services billed

855

170 women, 231 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Chronic kidney disease 51%
Arthritis 50%
Diabetes 45%
Heart failure 36%
Atrial fibrillation 28%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record